Natera, Inc. (NTRA)
Automate Your Wheel Strategy on NTRA
With Tiblio's Option Bot, you can configure your own wheel strategy including NTRA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NTRA
- Rev/Share 13.5881
- Book/Share 9.1998
- PB 17.1797
- Debt/Equity 0.1578
- CurrentRatio 3.8733
- ROIC -0.1557
- MktCap 21581253350.0
- FreeCF/Share 0.6322
- PFCF 253.3249
- PE -112.2307
- Debt/Assets 0.1129
- DivYield 0
- ROE -0.1829
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NTRA | RBC Capital Mkts | -- | Outperform | -- | $251 | March 13, 2025 |
| Initiation | NTRA | Barclays | -- | Overweight | -- | $200 | Jan. 23, 2025 |
News
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that data from more than 25 Signatera studies will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30 - June 3, 2025 in Chicago, IL. Together with its collaborators, Natera will showcase the clinical utility of Signatera across 10 different cancer types. This extraordinary breadth of data includes analys.
Read More
Natera: The Clues In Q1 Earnings
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Natera delivered stellar Q1 results, with revenue and EPS beating expectations, and strong volume growth, especially for its flagship Signatera product. Management sees significant upside for Signatera, projecting it could become a $5 billion annual product as both volumes and ASPs rise. Natera consistently outperforms its own conservative guidance, suggesting future earnings beats are likely, especially with unmodeled 'true-up' revenue.
Read More
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Natera (NTRA) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
Published: May 08, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, will present multiple datasets in breast cancer together with its collaborators at the 2025 ESMO Breast Cancer Annual Congress in Munich, Germany, taking place from May 14-17, 2025. Results from the I-SPY 2 clinical trial, sponsored and operated by Quantum Leap Healthcare Collaborative, will be shared in a mini-oral presentation on May 16, 2025. The report includes data from 712.
Read More
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) published a new study1 evaluating the performance of Prospera Heart with DQS to detect allograft rejection. Prospera with DQS leverages a two-threshold algorithm, combining the traditional donor fraction (dd-cfDNA %, measuring dd-cfDNA as a fraction of total cfDNA) and donor quantity score (DQS, estimating the to.
Read More
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Published: March 17, 2025 by: Seeking Alpha
Sentiment: Positive
Natera Inc. shows robust growth with high margins, a strong genetic testing portfolio, and a recent pullback offering an attractive entry point for investors.
Read More
Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Natera, Inc. (NTRA) Q4 2024 Earnings Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Natera, Inc. (NASDAQ:NTRA ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mike Brophy - Chief Financial Officer Steve Chapman - Chief Executive Officer Alexey Aleshin - GM Oncology, CMO Solomon Moshkevich - President, Clinical Diagnostics John Fesko - President and Chief Business Officer Conference Call Participants Doug Schenkel - Wolfe Research Rachel Vatnsdal - JPMorgan Tejas Savant - Morgan Stanley Tycho Peterson - Jefferies Puneet Souda - Leerink Partners Catherine Schulte - Baird Daniel Brennan - TD Cowen Dan Leonard - UBS Subbu Nambi - Guggenheim Operator Welcome everyone to Natera's 2024 Fourth Quarter …
Read More
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
Published: February 25, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services Program (MolDX) for patients with non-small cell lung cancer (NSCLC). This coverage applies to patients with stage I-III NSCLC with resectable or unresectable disease in the surveillance setting. It expands upon preexistin.
Read More
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) molecular residual disease (MRD) testing in the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for colon cancer, rectal cancer, and merkel cell carcinoma (MCC). In its updated guidelines for colon cancer1 and for rectal cancer2, NCCN now includes ctDNA as a high risk factor for recurrence in.
Read More
About Natera, Inc. (NTRA)
- IPO Date 2015-07-01
- Website https://www.natera.com
- Industry Medical - Diagnostics & Research
- CEO Mr. Steven Leonard Chapman
- Employees 4424